David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“FLAURA2 the standard of care for our first-line treatment of EGFR-mutated NSCLC patients in 2026.
Yes, with easy and logical adoption in many countries, as brilliantly presented by Pr Rolf Stahel during the lung session here in Egypt.”
More posts about NSCLC.